Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Am J Med Genet A
2013 Aug 01;161A8:2040-6. doi: 10.1002/ajmg.a.36056.
Show Gene links
Show Anatomy links
A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome.
Rienhoff HY
,
Yeo CY
,
Morissette R
,
Khrebtukova I
,
Melnick J
,
Luo S
,
Leng N
,
Kim YJ
,
Schroth G
,
Westwick J
,
Vogel H
,
McDonnell N
,
Hall JG
,
Whitman M
.
???displayArticle.abstract???
The transforming growth factor β (TGF-β) family of growth factors are key regulators of mammalian development and their dysregulation is implicated in human disease, notably, heritable vasculopathies including Marfan (MFS, OMIM #154700) and Loeys-Dietz syndromes (LDS, OMIM #609192). We described a syndrome presenting at birth with distal arthrogryposis, hypotonia, bifid uvula, a failure of normal post-natal muscle development but no evidence of vascular disease; some of these features overlap with MFS and LDS. A de novo mutation in TGFB3 was identified by exome sequencing. Several lines of evidence indicate the mutation is hypomorphic suggesting that decreased TGF-β signaling from a loss of TGFB3 activity is likely responsible for the clinical phenotype. This is the first example of a mutation in the coding portion of TGFB3 implicated in a clinical syndrome suggesting TGFB3 is essential for both human palatogenesis and normal muscle growth.
Figure 1. Pictures of the proband at ages 17 months, 36 months, and 6 years. Evident at age 17 months are the prominent eyes, hypertelorism, tubular nose, and retrognathia. Evident at age 36 months are a normal ear, retrognathia, and less pronounced hypertelorism. At age 6 years the inner canthal distance was within normal limits.
Figure 2. Picture of the proband at age 30 months with V.A. McKusick, M.D. Evident in the proband are the blue sclera, the well-placed and normal ear, tubular nose with metopic ridge, mild hyperterlorism, retrognathia, and hypomalar eminences.
Figure 3. TGFB3C409Y does not activate TGF-β signaling. Constructs containing FLAG-tagged TGFB3WT and TGFB3C409Y were expressed in HEK293T cells and secreted FLAG-tagged proteins were immunoprecipitated under native conditions and normalized to anti-FLAG reactivity. Serial dilutions of these proteins were applied to HEK293T cells transfected with p3TP-Lux (TGF-β reporter) and pRL-CMV (normalizer). Error bars are standard error of the mean (N = 3).
Figure 4. TGFB3C409Y acts as a dominant inhibitor of TGF-β signaling. Indicated amount of synthetic mRNAs were microinjected into Xenopus embryos after fertilization, and embryos harvested at Stage 9 for Western blot analysis. A representative Western blot is shown in A. B–D: Quantitation of densitometric analysis of three independent experiments is shown, measuring phosphorylated SMAD (pSMAD2) activation (pSMAD2/total SMAD2 ratio), pERK activation (pERK/ERK ratio), and total SMAD2, ERK, and cytoplasmic actin levels, respectively, following injection of mRNAs as indicated. Data are presented with error bars representing standard error of the mean. For each experiment, the intensity Western signal was standardized relative to the wild type TGFB/TGFBR2 co-injected condition (lane 3 of panels B–D).
Figure 5. TGFB3C409Y does not disrupt BMP signaling during Xenopus gastrulation. Indicated amounts of synthetic mRNAs for human TGFB3, TGFB3C409Y and Xenopus Noggin were injected into Xenopus laevis embryos to assay perturbations of BMP signaling during gastrulation. The levels of C-terminal phosphorylated SMAD1 (pSMAD1) were examined by immunoblotting. SMAD1 and actin were used as loading controls. Pictured in the lower panel are intact embryos; the BMPR antagonist Noggin disrupts gastrulation while TGFB3C409Y does not.
Amthor,
Myostatin imposes reversible quiescence on embryonic muscle precursors.
2006,
Pubmed
Brunner,
Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity.
1992,
Pubmed
Cohn,
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.
2007,
Pubmed
Daly,
Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth.
2008,
Pubmed
Daopin,
Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily.
1992,
Pubmed
,
Xenbase
Faure,
Endogenous patterns of TGFbeta superfamily signaling during early Xenopus development.
2000,
Pubmed
,
Xenbase
García-Castro,
N-Cadherin, a cell adhesion molecule involved in establishment of embryonic left-right asymmetry.
2000,
Pubmed
Holm,
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
2011,
Pubmed
Kalluri,
The basics of epithelial-mesenchymal transition.
2009,
Pubmed
Lee,
Induction and molecular signature of pathogenic TH17 cells.
2012,
Pubmed
Lee,
Regulation of muscle mass by myostatin.
2004,
Pubmed
Manceau,
Myostatin promotes the terminal differentiation of embryonic muscle progenitors.
2008,
Pubmed
Matyas,
De novo mutation of the latency-associated peptide domain of TGFB3 in a patient with overgrowth and Loeys-Dietz syndrome features.
2014,
Pubmed
Mittl,
The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding.
1996,
Pubmed
Nawshad,
TGFbeta3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development.
2003,
Pubmed
Neale,
Patterns and rates of exonic de novo mutations in autism spectrum disorders.
2012,
Pubmed
Ono,
BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells.
2011,
Pubmed
Pelton,
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development.
1991,
Pubmed
Pelton,
In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2.
1990,
Pubmed
Proetzel,
Transforming growth factor-beta 3 is required for secondary palate fusion.
1995,
Pubmed
Rienhoff,
Response to "De novo mutation of the TGFB3 latency-associated peptide domain in a patient with overgrowth and Loeys-Dietz syndrome features".
2014,
Pubmed
Wang,
Bmp signaling at the tips of skeletal muscles regulates the number of fetal muscle progenitors and satellite cells during development.
2010,
Pubmed
Wang,
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.
2010,
Pubmed
Yeo,
Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms.
2001,
Pubmed
,
Xenbase
